Catherine M. Engelbert - 07 Jun 2024 Form 4 Insider Report for Royalty Pharma plc (RPRX)

Role: Director
Signature: /s/ Sean Weisberg, as Attorney-in-Fact for Catherine M. Engelbert
Issuer symbol: RPRX
Transactions as of: 07 Jun 2024
Net transactions value: $0
Form type: 4
Filing time: 10 Jun 2024, 16:12:24 UTC
Previous filing: 03 Jan 2024
Next filing: 03 Jan 2025
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	RPRX	Class A Ordinary Shares	Award	$0	+9,293	+27%	$0.000000	43,514	07 Jun 2024	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Reflects an award of restricted stock units under the Issuer's 2020 Independent Director Equity Incentive Plan (the "Plan") that is generally scheduled to vest 100% on the earlier of (i) the one-year anniversary of the grant date and (ii) the date of the annual meeting of the Issuer's shareholders in the first calendar year following the grant date, subject to the terms of the Plan and the applicable award agreement thereunder.

Content

Reflects an award of restricted stock units under the Issuer's 2020 Independent Director Equity Incentive Plan (the "Plan") that is generally scheduled to vest 100% on the earlier of (i) the one-year anniversary of the grant date and (ii) the date of the annual meeting of the Issuer's shareholders in the first calendar year following the grant date, subject to the terms of the Plan and the applicable award agreement thereunder.